National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Foreign brand name:Cervarix
Abbreviation:HPV 16/18 L1 VLP/AS04 VAC
Code name:GSK-580299



Previous:human anti-alpha-v integrin monoclonal antibody, human anti-TGF-beta monoclonal antibody GC1008, human gp100 plasmid DNA vaccine, human monoclonal antibody 216, human monoclonal antibody B11-hCG beta fusion protein CDX-1307
Next:human prostate-specific membrane antigen plasmid DNA vaccine, HuMax-CD38, Hycamtin, Hycamtin Capsules, hycanthone

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov